The FDA has approved once-daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets from Eli Lilly and Boehringer Ingelheim for the treatment of type 2 diabetes (T2D) in adults.

Indications: Jentadueto XR is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus when treatment with both linagliptin and metformin is appropriate.

Dosage and administration: Individualize the starting dose of Jentadueto XR based on the patient’s current regimen. Do not exceed a total daily dose of linagliptin 5 mg and metformin 2000 mg. Give once daily with a meal.

Adverse reactions: The most common side effects include stuffy or runny nose, sore throat, and diarrhea.

Citation: US FDA approves once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. [news release]. Ridgefield, CT and Indianapolis, IN: Boehringer Ingelheim, Eli Lilly; May 31, 2016. https://investor.lilly.com/releaseDetail.cfm?ReleaseID=973469. Accessed June 6, 2016.